Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W M Glazer

Showing results (1-10 of 79) with videos related to

Pageof 8
Sort By:
The Journal of Clinical Psychiatry|March 30, 2000
Review of incidence studies of tardive dyskinesia associated with typical antipsychoticsW M Glazer
The Journal of Clinical Psychiatry|March 30, 2000
Expected incidence of tardive dyskinesia associated with atypical antipsychoticsW M Glazer
The Journal of Clinical Psychiatry|May 26, 1999
Does loxapine have "atypical" properties? Clinical evidenceW M Glazer
Employee Benefits Journal|June 1, 1993
Psychiatric treatment programs: the continuous services modelW M Glazer
Hospital & Community Psychiatry|November 1, 1994
What are "best practices?" Understanding the conceptW M Glazer
The Journal of Clinical Psychiatry|January 1, 1997
Olanzapine and the new generation of antipsychotic agents: patterns of useW M Glazer
The Journal of Clinical Psychiatry|March 21, 2000
Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicalityW M Glazer
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|January 1, 1996
The impact of managed care systems on relapse prevention and quality of life for patients with schizophreniaW M Glazer
QRB. Quality Review Bulletin|July 1, 1990
Risk management for extrapyramidal symptomsW M Glazer
Psychiatric Services (Washington, D.C.)|August 26, 1998
Defining best practices: a prescription for greater autonomyW M Glazer
Pageof 8

Showing results (1-10 of 79) with videos related to

Sort By:
Pageof 8
The Journal of Clinical Psychiatry|March 30, 2000
Review of incidence studies of tardive dyskinesia associated with typical antipsychoticsW M Glazer
The Journal of Clinical Psychiatry|March 30, 2000
Expected incidence of tardive dyskinesia associated with atypical antipsychoticsW M Glazer
The Journal of Clinical Psychiatry|May 26, 1999
Does loxapine have "atypical" properties? Clinical evidenceW M Glazer
Employee Benefits Journal|June 1, 1993
Psychiatric treatment programs: the continuous services modelW M Glazer
Hospital & Community Psychiatry|November 1, 1994
What are "best practices?" Understanding the conceptW M Glazer
The Journal of Clinical Psychiatry|January 1, 1997
Olanzapine and the new generation of antipsychotic agents: patterns of useW M Glazer
The Journal of Clinical Psychiatry|March 21, 2000
Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicalityW M Glazer
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|January 1, 1996
The impact of managed care systems on relapse prevention and quality of life for patients with schizophreniaW M Glazer
QRB. Quality Review Bulletin|July 1, 1990
Risk management for extrapyramidal symptomsW M Glazer
Psychiatric Services (Washington, D.C.)|August 26, 1998
Defining best practices: a prescription for greater autonomyW M Glazer
Pageof 8